Proinflammatory isoforms of IL-32 as novel and robust biomarkers for control failure in HIV-infected slow progressors

HIV-infected slow progressors (SP) represent a heterogeneous group of subjects who spontaneously control HIV infection without treatment for several years while showing moderate signs of disease progression. Under conditions that remain poorly understood, a subgroup of these subjects experience fail...

Full description

Bibliographic Details
Main Authors:	El-Far, Mohamed, Kouassi, Pascale, Sylla, Mohamed, Zhang, Yuwei, Fouda, Ahmed, Fabre, Thomas, Goulet, Jean-Philippe, van Grevenynghe, Julien, Lee, Terry, Singer, Joel, Harris, Marianne, Baril, Jean-Guy, Trottier, Benoit, Ancuta, Petronela, Routy, Jean-Pierre, Bernard, Nicole, Tremblay, Cécile L.
Format:	Online
Language:	English
Published:	Nature Publishing Group 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792165/

id	pubmed-4792165
recordtype	oai_dc
spelling	pubmed-47921652016-03-16 Proinflammatory isoforms of IL-32 as novel and robust biomarkers for control failure in HIV-infected slow progressors El-Far, Mohamed Kouassi, Pascale Sylla, Mohamed Zhang, Yuwei Fouda, Ahmed Fabre, Thomas Goulet, Jean-Philippe van Grevenynghe, Julien Lee, Terry Singer, Joel Harris, Marianne Baril, Jean-Guy Trottier, Benoit Ancuta, Petronela Routy, Jean-Pierre Bernard, Nicole Tremblay, Cécile L. Article HIV-infected slow progressors (SP) represent a heterogeneous group of subjects who spontaneously control HIV infection without treatment for several years while showing moderate signs of disease progression. Under conditions that remain poorly understood, a subgroup of these subjects experience failure of spontaneous immunological and virological control. Here we determined the frequency of SP subjects who showed loss of HIV control within our Canadian Cohort of HIV+ Slow Progressors and identified the proinflammatory cytokine IL-32 as a robust biomarker for control failure. Plasmatic levels of the proinflammatory isoforms of IL-32 (mainly β and γ) at earlier clinic visits positively correlated with the decline of CD4 T-cell counts, increased viral load, lower CD4/CD8 ratio and levels of inflammatory markers (sCD14 and IL-6) at later clinic visits. We present here a proof-of-concept for the use of IL-32 as a predictive biomarker for disease progression in SP subjects and identify IL-32 as a potential therapeutic target. Nature Publishing Group 2016-03-15 /pmc/articles/PMC4792165/ /pubmed/26978598 http://dx.doi.org/10.1038/srep22902 Text en Copyright © 2016, Macmillan Publishers Limited http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	El-Far, Mohamed Kouassi, Pascale Sylla, Mohamed Zhang, Yuwei Fouda, Ahmed Fabre, Thomas Goulet, Jean-Philippe van Grevenynghe, Julien Lee, Terry Singer, Joel Harris, Marianne Baril, Jean-Guy Trottier, Benoit Ancuta, Petronela Routy, Jean-Pierre Bernard, Nicole Tremblay, Cécile L.
spellingShingle	El-Far, Mohamed Kouassi, Pascale Sylla, Mohamed Zhang, Yuwei Fouda, Ahmed Fabre, Thomas Goulet, Jean-Philippe van Grevenynghe, Julien Lee, Terry Singer, Joel Harris, Marianne Baril, Jean-Guy Trottier, Benoit Ancuta, Petronela Routy, Jean-Pierre Bernard, Nicole Tremblay, Cécile L. Proinflammatory isoforms of IL-32 as novel and robust biomarkers for control failure in HIV-infected slow progressors
author_facet	El-Far, Mohamed Kouassi, Pascale Sylla, Mohamed Zhang, Yuwei Fouda, Ahmed Fabre, Thomas Goulet, Jean-Philippe van Grevenynghe, Julien Lee, Terry Singer, Joel Harris, Marianne Baril, Jean-Guy Trottier, Benoit Ancuta, Petronela Routy, Jean-Pierre Bernard, Nicole Tremblay, Cécile L.
author_sort	El-Far, Mohamed
title	Proinflammatory isoforms of IL-32 as novel and robust biomarkers for control failure in HIV-infected slow progressors
title_short	Proinflammatory isoforms of IL-32 as novel and robust biomarkers for control failure in HIV-infected slow progressors
title_full	Proinflammatory isoforms of IL-32 as novel and robust biomarkers for control failure in HIV-infected slow progressors
title_fullStr	Proinflammatory isoforms of IL-32 as novel and robust biomarkers for control failure in HIV-infected slow progressors
title_full_unstemmed	Proinflammatory isoforms of IL-32 as novel and robust biomarkers for control failure in HIV-infected slow progressors
title_sort	proinflammatory isoforms of il-32 as novel and robust biomarkers for control failure in hiv-infected slow progressors
description	HIV-infected slow progressors (SP) represent a heterogeneous group of subjects who spontaneously control HIV infection without treatment for several years while showing moderate signs of disease progression. Under conditions that remain poorly understood, a subgroup of these subjects experience failure of spontaneous immunological and virological control. Here we determined the frequency of SP subjects who showed loss of HIV control within our Canadian Cohort of HIV+ Slow Progressors and identified the proinflammatory cytokine IL-32 as a robust biomarker for control failure. Plasmatic levels of the proinflammatory isoforms of IL-32 (mainly β and γ) at earlier clinic visits positively correlated with the decline of CD4 T-cell counts, increased viral load, lower CD4/CD8 ratio and levels of inflammatory markers (sCD14 and IL-6) at later clinic visits. We present here a proof-of-concept for the use of IL-32 as a predictive biomarker for disease progression in SP subjects and identify IL-32 as a potential therapeutic target.
publisher	Nature Publishing Group
publishDate	2016
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792165/
_version_	1613551970993307648

Proinflammatory isoforms of IL-32 as novel and robust biomarkers for control failure in HIV-infected slow progressors

Similar Items